Deo Rajat, Khera Amit, McGuire Darren K, Murphy Sabina A, Meo Neto Januario de P, Morrow David A, de Lemos James A
Donald W. Reynolds Cardiovascular Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
J Am Coll Cardiol. 2004 Nov 2;44(9):1812-8. doi: 10.1016/j.jacc.2004.07.047.
We sought to evaluate the association between plasma levels of monocyte chemoattractant protein (MCP)-1 and the risk for subclinical atherosclerosis.
Monocyte chemoattractant protein is a chemokine that recruits monocytes into the developing atheroma and may contribute to atherosclerotic disease development and progression. Plasma levels of MCP-1 are independently associated with prognosis in patients with acute coronary syndromes, but few population-based data are available from subjects in earlier stages of atherosclerosis.
In the Dallas Heart Study, a population-based probability sample of adults in Dallas County </=65 years old, plasma levels of MCP-1 were measured in 3,499 subjects and correlated with traditional cardiovascular risk factors, high-sensitivity C-reactive protein (hs-CRP), and coronary artery calcium (CAC) measured by electron beam computed tomography.
Higher MCP-1 levels were associated with older age, white race, family history of premature coronary disease, smoking, hypertension, diabetes, hypercholesterolemia, and higher levels of hs-CRP (p < 0.01 for each). Similar associations were observed between MCP-1 and risk factors in the subgroup of participants without detectable CAC. Compared with the subjects in the lowest quartile of MCP-1, the odds of prevalent CAC (CAC score >/=10) for subjects in the second, third, and fourth quartiles were 1.30 (95% confidence interval [CI] 0.99 to 1.73), 1.60 (95% CI 1.22 to 2.11), and 2.02 (95% CI 1.54 to 2.63), respectively. The association between MCP-1 and CAC remained significant when adjusted for traditional cardiovascular risk factors, but not when further adjusted for age.
In a large population-based sample, plasma levels of MCP-1 were associated with traditional risk factors for atherosclerosis, supporting the hypothesis that MCP-1 may mediate some of the atherogenic effects of these risk factors. These findings support the potential role of MCP-1 as a biomarker target for drug development.
我们试图评估血浆单核细胞趋化蛋白（MCP）-1水平与亚临床动脉粥样硬化风险之间的关联。
单核细胞趋化蛋白是一种趋化因子，可将单核细胞募集到正在形成的动脉粥样硬化斑块中，并可能促进动脉粥样硬化疾病的发生和发展。MCP-1的血浆水平与急性冠脉综合征患者的预后独立相关，但关于动脉粥样硬化早期阶段受试者的基于人群的数据很少。
在达拉斯心脏研究中，对达拉斯县年龄≤65岁的成年人进行基于人群的概率抽样，测量了3499名受试者的MCP-1血浆水平，并将其与传统心血管危险因素、高敏C反应蛋白（hs-CRP）以及通过电子束计算机断层扫描测量的冠状动脉钙化（CAC）进行关联分析。
较高的MCP-1水平与年龄较大、白种人、早发冠心病家族史、吸烟、高血压、糖尿病、高胆固醇血症以及较高的hs-CRP水平相关（每项p<0.01）。在未检测到CAC的参与者亚组中，MCP-1与危险因素之间也观察到类似的关联。与MCP-1最低四分位数的受试者相比，第二、第三和第四四分位数受试者发生现患CAC（CAC评分≥10）的比值比分别为1.30（95%置信区间[CI]0.99至1.73）、1.60（95%CI 1.22至2.11）和2.02（95%CI 1.54至2.63）。在调整传统心血管危险因素后，MCP-1与CAC之间的关联仍然显著，但在进一步调整年龄后则不显著。
在一个基于人群的大样本中，MCP-1的血浆水平与动脉粥样硬化的传统危险因素相关，支持了MCP-1可能介导这些危险因素的一些致动脉粥样硬化作用的假说。这些发现支持了MCP-1作为药物开发生物标志物靶点的潜在作用。
